Aspire Biopharma Holdings Inc. held a special meeting of stockholders on November 4, 2025. At the meeting, stockholders approved granting the board discretionary authority to amend the certificate of incorporation to implement a reverse stock split at a ratio ranging from one-for-five to one-for-forty, to be determined at the board's discretion and effected within one year. Stockholders also approved the issuance of more than 19.99% of the outstanding shares of common stock upon exercise of certain convertible promissory notes, as well as the floor price at which the notes may be converted.